Hormone therapy in postmenopausal women and risk of endometrial hyperplasia-Reference-Cited by-同舟云学术

Hormone therapy in postmenopausal women and risk of endometrial hyperplasia

Published:2012-08-15 Issue: Volume: Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Furness Susan¹,Roberts Helen²,Marjoribanks Jane²,Lethaby Anne²

Affiliation:

1. School of Dentistry, The University of Manchester; Cochrane Oral Health Group; Coupland III Building, Oxford Rd Manchester UK M13 9PL

2. University of Auckland; Obstetrics and Gynaecology; Private Bag 92019 Auckland New Zealand 1003

Publisher

Wiley

Subject

Pharmacology (medical)

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/14651858.CD000402.pub4/fullpdf

Reference195 articles.

1. Comparison of two continuous combined estrogen progestogen regimens in postmenopausal women: a randomised trial;AinMelk;Fertility & Sterility,1996

2. Acceptability and patterns of endometrial bleeding in estradiol-based HRT regimens: a comparative study of cyclical sequential combinations of trimegestone or norethisterone acetate;Al-Azzawi;Climacteric,2001

3. Long-term safety of drospirinone-estradiol for hormone therapy: a randomised, double-blind, multicenter trial;Archer;Menopause,2005

4. Bouchard P Addo S Spielmann D The Trimegestone 301 Study Group A comparison of the effects of continuous combined regimens of 1mg 17B-estradiol and trimegestone with continuous combined estradiol and norethisterone acetate upon the bleeding profile and safety in postmenopausal women for up to 2 years Climacteric 2002 145

5. Bleeding profile and endometrial safety of continuous combined regimens 1 mg 17beta-estradiol/trimegestone versus 1 or 2 mg 17beta-estradiol/norethisterone acetate in postmenopausal women;Bouchard;Gynecological Endocrinology,2005

Cited by 105 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A focus on progestogens in hormone replacement therapy;The Obstetrician & Gynaecologist;2023-10

2. Increased Risk of Breast Fibroadenomas Among Obese and Postmenopausal Women With Uterine Fibroids;Cureus;2023-08-15

3. Spray dried progesterone formulations for carrier free dry powder inhalation;European Journal of Pharmaceutics and Biopharmaceutics;2023-08

4. Potential Therapeutic Options for Premature Ovarian Insufficiency: Experimental and Clinical Evidence;Reproductive Sciences;2023-07-17

5. A phase 1/2, open-label, parallel group study to evaluate the safety and pharmacokinetics of DARE-HRT1 (80 μg estradiol/4 mg progesterone and 160 μg estradiol/8 mg progesterone intravaginal rings) over 12 weeks in healthy postmenopausal women;Menopause;2023-06-20